Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics

Rhea-AI Summary

Biophytis (NBIS) and LynxKite expanded a partnership on March 13, 2026 to accelerate AI-driven drug discovery for longevity therapeutics, starting with the MASSIVE program targeting Mas receptor activators for sarcopenia.

The collaboration combines Biophytis' MasR expertise with LynxKite's AI, chemoinformatics and GPU-scaled computation, and is supported by Singapore's Enterprise Singapore. Key aims include AI-enabled structure-based design, molecule generation, synthesis/testing, and lead selection with patent protection for preclinical development.

News Market Reaction – NBIS

+4.54%

34 alerts

+4.54% News Effect

+3.5% Peak in 19 min

+$1.28B Valuation Impact

$29.45B Market Cap

0.3x Rel. Volume

On the day this news was published, NBIS gained 4.54%, reflecting a moderate positive market reaction. Argus tracked a peak move of +3.5% during that session. Our momentum scanner triggered 34 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $1.28B to the company's valuation, bringing the market cap to $29.45B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Supported enterprises: more than 100 enterprises Experience duration: over 10 years RIE plan horizon: 2030

3 metrics

Supported enterprises more than 100 enterprises LynxKite founding team track record

Experience duration over 10 years LynxKite founding team experience

RIE plan horizon 2030 Singapore Research, Innovation and Enterprise (RIE) 2030 plan

Market Reality Check

Price: $157.75 Vol: Volume 13.1M is slightly ...

normal vol

$157.75 Last Close

Volume Volume 13.1M is slightly below 20-day average 13.9M (relative volume 0.94x). normal

Technical Price 108.04 is trading above 200-day MA at 84.09, indicating a pre-news uptrend.

Peers on Argus

NBIS was down 3.53% pre-news, while 2 high-affinity peers (Z, ZG) in momentum sc...

2 Up

NBIS was down 3.53% pre-news, while 2 high-affinity peers (Z, ZG) in momentum scanner moved up (median about 4.4%). This opposite direction points to stock-specific dynamics rather than a sector-wide move.

Previous AI Reports

5 past events · Latest: Mar 04 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 04	AI factory approval	Positive	+12.7%	City Council approval enabling construction of largest US AI factory campus.
Dec 17	AI cloud upgrade	Positive	-6.8%	Launch of Nebius AI Cloud 3.1 with next-gen NVIDIA Blackwell Ultra compute.
Dec 10	AI startup awards	Positive	-2.9%	Robotics & Physical AI awards granting $1.5M in compute credits to startups.
Nov 05	Inference platform	Positive	+5.8%	Launch of Nebius Token Factory for large-scale AI inference on AI Cloud 3.0.
Oct 16	AI cloud launch	Positive	-2.2%	Introduction of Nebius AI Cloud 3.0 “Aether” with security and compliance focus.

Pattern Detected

AI-tagged announcements are generally positive but price often diverged, with 3 of 5 past AI news days closing down despite constructive product or platform launches.

Recent Company History

Recent AI-tagged news for Nebius shows a consistent focus on scaling infrastructure and platform capabilities. In Oct–Nov 2025 it launched Nebius AI Cloud 3.0 “Aether” and Nebius Token Factory for production inference. In Dec 2025 it rolled out AI Cloud 3.1 with NVIDIA Blackwell Ultra hardware and hosted a Robotics & Physical AI awards summit. On Mar 4, 2026, approval for a gigawatt-scale AI factory drove a 12.65% move, underscoring investor attention to large-scale AI capacity.

Historical Comparison

+1.3% avg move · Over the past 5 AI-tagged announcements, NBIS moved an average of 1.31%, with mixed up/down reaction...

AI

+1.3%

Average Historical Move AI

Over the past 5 AI-tagged announcements, NBIS moved an average of 1.31%, with mixed up/down reactions, showing that even strong AI narratives have produced inconsistent price responses.

AI news has progressed from launching secure AI cloud (3.0), to a production inference platform and Blackwell-based 3.1 upgrade, and most recently to gigawatt-scale AI factory approval.

Market Pulse Summary

This announcement highlights an expanded AI-driven drug discovery partnership focused on longevity, ...

Analysis

This announcement highlights an expanded AI-driven drug discovery partnership focused on longevity, including sarcopenia and dry age-related macular degeneration. For Nebius, it adds another AI use case on top of recent cloud and infrastructure milestones, such as the gigawatt-scale AI factory approval on Mar 4, 2026. Investors may watch how similar AI-tagged news historically produced mixed price reactions and track forthcoming execution metrics, IP milestones, and partner adoption in this longevity-focused collaboration.

Key Terms

mas receptor, pharmacokinetics, in vitro, in vivo, +2 more

6 terms

mas receptor medical

"identify and develop Mas receptor (MasR) activator drug candidates targeting sarcopenia"

A cell-surface protein called the MAS receptor acts like a lock that certain signaling molecules (notably angiotensin-(1-7)) fit into, producing effects that relax blood vessels and reduce inflammation and scarring in organs. Investors care because drugs that activate or block this receptor can alter outcomes in heart, kidney and lung diseases, so advances or setbacks in MAS receptor research can materially affect the value and prospects of related biotech pipelines and clinical programs.

pharmacokinetics medical

"assess biological activity, safety, and pharmacokinetics."

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

in vitro medical

"via feedback loops from in vitro and in vivo validation of candidates."

In vitro describes laboratory tests performed on cells, tissues, or biological molecules outside a living body—literally “in glass,” such as in test tubes or dishes. For investors, in vitro results are an early sign that a drug or technology has a desired effect under controlled conditions, but they don’t guarantee it will work or be safe in animals or people; think of them as a prototype tested on a bench rather than in real-world use.

in vivo medical

"via feedback loops from in vitro and in vivo validation of candidates."

In vivo describes tests or experiments performed inside a living organism, such as an animal or human, to observe how a drug, device or biological process behaves in a real, functioning body. Investors care because in vivo results reveal safety, effectiveness and possible side effects that lab tests cannot, much like road-testing a prototype car in traffic rather than only on a bench — outcomes can strongly influence regulatory approval, clinical success and a company’s valuation.

chemoinformatics medical

"LynxKite brings state-of-the-art AI technologies, chemoinformatics, and software engineering"

Chemoinformatics is the use of computers and data tools to organize, visualize and predict the behavior of chemical compounds, essentially treating molecules as data that can be searched and modeled. For investors it matters because these tools speed and lower the cost of finding promising drugs or materials, reduce scientific uncertainty, and can increase the value of research assets by enabling faster go/no-go decisions and more efficient licensing or development pathways.

gpu technical

"coupled with scaling GPU computation on the latest generation of NVIDIA toolkits"

A GPU (graphics processing unit) is a specialized computer chip designed to handle many calculations at once, originally for rendering images and video but now widely used for tasks like artificial intelligence, data analysis and high-performance computing. Investors watch GPU demand and prices because strong sales often signal growth for chip makers and their customers, affect profit margins and capital spending, and can forecast wider trends in gaming, AI adoption and cloud services.

AI-generated analysis. Not financial advice.

• Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies
• This partnership will generate revenue through:
  • A computational longevity platform, including unique curated datasets and accelerated computation methods relevant for longevity research
  • Next-generation drug candidates against sarcopenia
  • Next generation drug candidates for dry age-related macular degeneration 

SINGAPORE, PARIS and CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Lynxkite is expanding its partnership with Biophytis SA (Euronext Growth Paris: ALBPS) ("Biophytis"), starting with  the MASSIVE project (MAS Receptor Synthetic Innovation & Virtual Engineering for Sarcopenia therapy) and plans to expand the platform to other modalities. This strategic initiative, also supported by Singapore's Enterprise Singapore, is aligned with priority target areas in Singapore's Research, Innovation and Enterprise (RIE) 2030 plan.

LynxKite Technologies, a leader in advanced analytics and artificial intelligence, known for its flagship open-source platform LynxKite, will integrate AI computational methods relevant for longevity research into its computational orchestration platform. With over a decade of experience, the founding team of LynxKite has supported more than 100 global enterprises — including major players such as Roche, AstraZeneca and Hummingbird Biosciences — in analyzing complex data using graph-based and generative AI approaches.

The first MASSIVE project aims to identify and develop Mas receptor (MasR) activator drug candidates targeting sarcopenia, a degenerative muscle disease associated with aging that affects millions of elderly people worldwide. Biophytis contributes its deep expertise in age-related diseases, its preclinical experience in MasR-linked indications, and its expertise in Mas receptor pharmacology. LynxKite brings state-of-the-art AI technologies, chemoinformatics, and software engineering coupled with scaling GPU computation on the latest generation of NVIDIA toolkits and neoclouds such as Nebius. Together, the partners strengthen Biophytis' strategic drug discovery program, aligned with its longevity-focused strategy and positioning.

The project's key objectives include:

1. Modeling the Mas receptor for structure-based drug design using AI and protein prediction tools.
2. Designing and prioritizing synthetic drug candidates through AI-guided molecule generation and predictive filtering.
3. Synthesizing and testing promising MasR activators to assess biological activity, safety, and pharmacokinetics.
4. Selecting and protecting the lead candidate through patent filings in preparation for preclinical development.
5. Developing and validating the AI software via feedback loops from in vitro and in vivo validation of candidates.

"The launch of MASSIVE marks a decisive step in our longevity strategy, combining our clinical expertise with LynxKite's innovative AI to accelerate the discovery of transformative therapies against sarcopenia," said Stanislas Veillet, CEO of Biophytis.

Gyorgy Lajtai, CEO of LynxKite, added: "We are proud to collaborate with Biophytis on pioneering computational longevity through our LynxKite platfom, which demonstrates how LynxKite can revolutionize discovery by designing, integrating and orchestrating relevant computational tools in diverse modalities."

About LynxKite

LynxKite Technologies Pte Ltd, headquartered in Singapore with offices in the United States, Switzerland The LynxKite platform combines graph analytics, biological language models, while directly managing, optimizing, and autoscaling GPU resources to efficiently run complex pipelines such as NVIDIA NIM Microservices. Building on more than a decade of experience in graph and enterprise AI, LynxKite collaborates with research institutions, technology partners, and industry leaders to accelerate scientific discovery and advanced analytics. For more information, please visit https://lynxkite.com.

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company's ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.

About Nebius
Nebius, the AI cloud company, is building the full-stack platform for developers and companies to take charge of their AI future — from data and model training to production deployment. Founded on deep in-house technological expertise and operating at scale with a rapidly expanding global footprint, Nebius serves startups and enterprises building AI products, agents, and services worldwide. Nebius is listed on Nasdaq (NASDAQ: NBIS) and headquartered in Amsterdam. For more information, please visit www.nebius.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/biophytis-lynxkite-alliance-expands-to-turbocharge-ai-driven-drug-discovery-for-next-generation-longevity-therapeutics-302713532.html

SOURCE Biophytis; LynxKite Technologies

FAQ

What is the MASSIVE program announced by Biophytis (NBIS) and LynxKite on March 13, 2026?

MASSIVE is a joint project to discover Mas receptor activators for sarcopenia using AI-driven methods. According to Biophytis, it focuses on modeling MasR, AI molecule generation, synthesis, biological testing, and lead selection ahead of preclinical development.

How will the Biophytis (NBIS) and LynxKite alliance use AI in drug discovery?

They will integrate AI for structure-based design, generative molecule creation, and predictive filtering of candidates. According to LynxKite, the platform couples chemoinformatics, protein prediction tools and GPU-scaled computation to accelerate candidate prioritization and validation workflows.

What therapeutic targets will Biophytis (NBIS) pursue with LynxKite under the partnership?

The initial focus is Mas receptor activators targeting sarcopenia, with plans to expand to other longevity modalities. According to Biophytis, the partnership also aims to develop candidates for dry age-related macular degeneration and other longevity-relevant indications.

Does the Biophytis (NBIS)–LynxKite collaboration have external support or funding?

Yes, the initiative is supported by Singapore's Enterprise Singapore and aligns with RIE 2030 priorities. According to Biophytis, this strategic support complements the partners' resources for computational platform development and candidate validation.

What are the next steps and timelines for Biophytis (NBIS) and LynxKite's MASSIVE project?

Next steps include AI modeling of MasR, generation and prioritization of synthetic candidates, followed by synthesis, in vitro and in vivo testing, and patent filing for leads. According to Biophytis, these activities prepare selected candidates for preclinical development.